Clinical Proteomics: From Diagnosis to Therapy

Copyright © 2008 Wiley-VCH Verlag GmbH & Co. KGaA

Clinical Proteomics: From Diagnosis to Therapy

Editor(s): Jennifer E. Van Eyk, Michael J. Dunn

Published Online: 8 APR 2008

Print ISBN: 9783527316373

Online ISBN: 9783527622153

DOI: 10.1002/9783527622153

About this Book

Product Information

About The Product

Unparalleled in its scope and depth, this book brings together proteomic approaches in diagnosis and treatment from all clinical fields, including clinical toxicology. The result is a new discipline in molecular medicine that will revolutionize the treatment and prevention of cancer, stroke and other severe diseases.
Following an overview of clinical proteomics, the authors look at the technologies available, before moving on to cancer, cardiopulmonary disease, diabetes and stroke. A whole section is devoted to toxicity and the work is rounded off with a discussion of the future of clinical proteomics.

Table of contents

    1. You have free access to this content
      Front Matter (pages I–XXXIII)

  2. Part I: Technologies

    1. Chapter 1

      Preanalytical Issues in Clinical Proteomic Studies (pages 1–12)

      Roisean E. Ferguson and Rosamonde E. Banks

    2. Chapter 2

      Protein Separation by Two-Dimensional Electrophoresis (pages 13–29)

      Pamela M. Donoghue, Miroslava Stastna and Prof. Dr. Michael J. Dunn

    3. Chapter 3

      Protein Separation: Liquid Chromatography (pages 31–51)

      Miroslava Stastna and Dr. Jennifer Van Eyk

    4. Chapter 4

      HPLC in Protein Discovery (pages 53–60)

      Timothy J. Barder

    5. Chapter 5

      IEF Analysis of Peptides for Biomarkers Discovery (pages 61–71)

      Ali R. Vaezzadeh, Catherine G. Zimmermann-Ivol, Jacques Deshusses, Alexander Scherl and Denis F. Hochstrasser

    6. Chapter 6

      Capillary Electrophoretic Separations for Clinical Proteomics (pages 73–88)

      Brian M. Balgley, Weijie Wang, Xueping Fang, Don L. DeVoe and Cheng S. Lee

    7. Chapter 7

      Quantitative Proteomics Using Nano-LC with High Accuracy Mass Spectrometry (pages 89–100)

      Ljiljana Paša-Tolić, Jon M. Jacobs, Wei-Jun Qian and Richard D. Smith

    8. Chapter 8

      Antibody Microarrays for Protein and Glycan Detection (pages 101–111)

      Songming Chen and Brian B. Haab

    9. Chapter 9

      Biomarker Identification: The Role of Experimental Design, Statistics, and Data Sharing (pages 113–120)

      Marc R. Wilkins

  3. Part II: Cancer

    1. Chapter 10

      Applications of Stable Isotope Tagging Based Quantitative Proteomics in Cancer Research (pages 121–143)

      Ru Chen, Teresa A. Brentnall and Ruedi Aebersold

    2. Chapter 11

      Two-Dimensional Liquid Separations, Protein Microarrays, and Mass Spectrometry in Comprehensive Analysis of Posttranslational Modifications and Biomarker Discovery in Cancers (pages 145–164)

      Tasneem H. Patwa, Jia Zhao, David E. Misek and David M. Lubman

    3. Chapter 12

      Development and Use of Reversed-Phase Protein Microarrays for Clinical Applications (pages 165–175)

      Virginia Espina, Julia Wulfkuhle, Valerie S. Calvert, Kirsten H. Edmiston, Lance A. Liotta and Emanuel F. Petricoin

    4. Chapter 13

      Cyclin-Dependent Kinase Inhibitors and Cancer: Usefulness of Proteomic Approaches in Assessment of the Molecular Mechanisms and Efficacy of Novel Therapeutics (pages 177–202)

      Marian Hajduch, Helena Skalnikova, Petr Halada, David Vydra, Petr Dzubak, Marta Dziechciarkova, Miroslav Strnad, Danuta Radioch, Suresh Jivan Gadher and Hana Kovarova

  4. Part III: Cardiac Disease

    1. Chapter 14

      Diagnostic Markers for Monitoring Heart Transplant Rejection (pages 203–215)

      Dr. Ciara A. McManus, Professor Marlene L. Rose and Prof. Dr. Michael J. Dunn

    2. Chapter 15

      The Study of Microheterogeneity in Human Plasma Proteins: Application to Acute Myocardial Infarction (pages 217–229)

      Randall W. Nelson, Urban A. Kiernan, Dobrin Nedelkov, Kemmons A. Tubbs and Eric E. Niederkofler

    3. Chapter 16

      Discovery of Biomarkers for Cardiovascular Diseases (pages 231–240)

      Anthony O. Gramolini and Andrew Emili

    4. Chapter 17

      Development of Biomarker Development Pipeline: Search for Myocardial Ischemia Biomarkers (pages 241–261)

      Qin Fu, Shijun Sheng and Dr. Jennifer E. Van Eyk

    5. Chapter 18

      The Albuminome as a Tool for Biomarker Discovery (pages 263–278)

      Rebekah L. Gundry and Robert J. Cotter

    6. Chapter 19

      Application of Metabolomics to Cardiovascular Biomarker and Pathway Discovery (pages 279–293)

      Gregory D. Lewis and Robert E. Gerszten

  5. Part IV: Vascular Disease: Pulmonary, Diabetes and Brain

    1. Chapter 20

      Urinary Biomarkers in Diabetic Nephropathy and Other Glomerular Diseases (pages 295–322)

      John M. Arthur and T. Brian Powell

    2. Chapter 21

      Pulmonary Proteomics (pages 323–347)

      Jan Hirsch, Lorraine B. Ware and Michael A. Matthay

    3. Chapter 22

      Proteomics Providing Insights into Major Psychiatric Disorders (pages 349–377)

      Melanie Föcking, Kyla Pennington, Jane English, Prof. Dr. Michael Dunn and David Cotter

  6. Part V: Toxicity, Bacterial and Viral Infections

    1. Chapter 23

      Redox Proteomics Analysis of Oxidative Modified Brain Proteins in Alzheimer's Disease and Mild Cognitive Impairment: Insights into the Progression of This Dementing Disorder (pages 379–401)

      Rukhsana Sultana and D. Allan Butterfield

    2. Chapter 24

      Toxicoproteomics: Correlating Tissue and Serum Proteomics in Liver Injury (pages 403–433)

      B. Alex Merrick

    3. Chapter 25

      Biomarkers for Renal Disease and Uremic Toxins (pages 435–452)

      Eric Schiffer, Harald Mischak and Raymond C. Vanholder

    4. Chapter 26

      HIV and Other Viral Screens (pages 453–480)

      David R. Graham

  7. Part VI: Autoimmune Disease and Autoantibodies

    1. Chapter 27

      Application of Fungal Cyclic Peptides and Metabolites (pages 481–509)

      Jan Nedvěd, Miroslav Sulc, Alexandr Jegorov, Anastassios Giannakopulos and Vladimir Havlicek

    2. Chapter 28

      Microarray Approaches to Autoantibody Profiling (pages 511–532)

      John M. Astle and Thomas Kodadek

    3. Chapter 29

      Identification of Tumor Antigen Directed Autoantibodies (pages 533–547)

      Sandra Faca and Sam Hanash

    4. Chapter 30

      Antibody and Reverse Capture Protein Microarrays for Clinical Proteomics (pages 549–569)

      Harvey B. Pollard, Ofer Eidelman, Meera Srivastava, Catherine Joswik, Stephen Rothwell, Gregory P. Mueller, David M. Jacobowitz, William B. Guggino, Jerry Wright, Pamela L. Zeitlin and Cloud P. Paweletz

    5. Chapter 31

      Use of Antibody Microarrays in the Analysis of Inflammation, Autoimmunity, Viral Infection, and Cancer Metastases (pages 571–592)

      Rodney Lui, Angus Brown, Bosco Wu, Ming-Wei Lin, John Thompson, Filip Braet, Wayne Dyer, JoDee Lattimore, Peter Macdonald, Stephen Adelstein and Cristobal G. dos Remedios

  8. Part VII: Translation: Discovery to the Clinic

    1. Chapter 32

      The Future: Translation from Discovery to the Clinic – Roles of HUPO and Industry in Biomarker Discovery (pages 593–613)

      Gilbert S. Omenn and Peipei Ping

    2. Chapter 33

      Requirements of a Good Biomarker: Translation into the Clinical Laboratory (pages 615–631)

      Mario Plebani, Martina Zaninotto and Monica Maria Mion

    3. Chapter 34

      Translation of Protein Biomarkers for Clinical Development (pages 633–651)

      Ian McCaffery, V. Dan Fitzpatrick, Shen Wu Wang, John M. Rossi, Haifeng Bao, Sid V. Suggs, John Ferbas and Scott D. Patterson

    1. You have free access to this content
      Index (pages 653–659)

SEARCH